Olema Pharmaceuticals, Inc. Common Stock
Here’s whether Olema Pharmaceuticals, Inc. Common Stock (OLMA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: strong 1-year return of +144.9%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.48% over 10 days); RSI 26 — oversold; 3-month momentum negative (-35.6%); rising volume on a downtrend (distribution, 1.26x avg). Currently 71.6% off its 52-week high. Score: -5/7.
OLMA is trading below its 200-day MA ($16.87) — a key warning sign the longer-term trend is under pressure. An RSI of 25.9 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +144.9% compares to +24.4% for SPY (beat the market by 120.5%). The current 71.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.